Clinical Trial Update: Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CM313 as a subcutaneous injection for systemic lupus erythematosus is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CM313(SC) Injection (CM313)

Snippet

Sponsor: Keymed Biosciences Co.Ltd | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: NOT_YET_RECRUITING